| INTRODUCTION
Vestibular schwannomas (VSs) are benign, slow-growing tumours originating from Schwann cells of the vestibular part of the eighth cranial nerve. 1 They represent 6% of all intracranial tumours. 2 Patients with sporadic/unilateral VS most commonly present between their 40s and 60s, some with small intracanalicular tumours and others with larger extrameatal tumours expanding into the cerebellopontine angle (CPA). 3 Patients typically present with asymmetric sensorineural hearing loss (ASHL), asymmetric tinnitus and/or vertigo. 4 Currently, magnetic resonance imaging (MRI) is used to screen for VS in patients visiting the otolaryngology clinic with either ASHL confirmed by pure tone audiometry (PTA), complaints of vertigo with asymmetry on electronystagmography (ENG) or asymmetric tinnitus.
T1-weighted MRI of the CPA with contrast is considered the gold standard for detecting VS and is often used in combination with high-resolution T2 of the CPA and T2-weighted MRI of the whole brain to screen for other pathology. 5, 6 As the incidence of VS is only 3% in the screening population, MRI has a very low yield. 7 Taking into account other pathologies (eg meningioma, demyelinating disease) that can be found through MRI in this population,
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approximately 14% of all MRI scans will show abnormalities. 7 The other 86% of MRIs are negative and can be considered an inefficient use of resources and may cause unnecessary uncertainty for the patient. 8, 9 More efficient strategies could potentially avoid unnecessary
MRIs in the diagnosis of VS and thus potentially increase cost-effectiveness. Before research is initiated and money is spent to develop these new strategies, it is important to assess the potential benefits these strategies might have. In this cost analysis, we examined the potential savings that new diagnostic strategies could bring, compared to the current diagnostic strategy. These analyses are performed using a decision analytical model, which compares the expected costs of potential new and current diagnostic strategies.
| ME TH ODS
We developed a decision tree of the diagnostic process, as is shown in • Substantial savings could be generated if we would be able to further optimise the diagnosis of patients suspected of VS. This indicates that there is room for the development of innovative diagnostic strategies.
OP and other important pathology, because this allowed us to con- were considered not important, as no action was required after diagnosis. Also infarction was considered a non-important pathology. In the last step of the diagnostic process, a consultation in a tertiary hospital to determine course of action for all patients with VS or OIP was included.
| Strategies
We compared three hypothetical new strategies with the current diagnostic strategy (Table 1) . We varied the population that received MRI: all patients at risk, VS and OP, VS and OIP, and VS only. We assumed that all patients with VS were correctly diagnosed in each strategy (ie no false positives and false negatives) and all patients were eligible for MRI. Costs of general practitioner consultations and extra diagnostic tests (PTA, ENG, etc.) were not included, as the target population comprised patients who already received general practitioner consultation and these diagnostic tests.
| Probabilities
Probabilities were used to guide patients through the model, that is at each junction the cohort of patients was divided into two or more groups based on probabilities. When possible, we derived probabilities from literature through targeted systematic review (Table 2 ).
When no evidence was available in literature, we asked key opinion leaders to provide probabilities. All expert-based values were confirmed by at least two key opinion leaders (clinicians). Important probabilities were derived from Dawes et al who reported MRI findings from a series of 1139 patients at risk of VS. The overall probability to have pathology was 14.1%, from which we distinguished the probability to have VS (3.0%). Of the remaining 11.1% with other pathology, 20.5% was considered to be important. 7 
| Costs
We performed the cost analysis from a healthcare perspective, restricted to direct diagnostic costs. Other costs such as out of pocket expenses, travel costs and treatment costs were not included.
Costs were assessed in Euros (€) and based on the 2014 price level.
For the main results, we converted Euros to US Dollars with an exchange rate of 1.109 on October 24, 2016, to increase readability.
If possible, we derived unit costs (average costs incurred by producing one unit of a good or service) from the Dutch guideline for costing research. 10 Key costs in the diagnostic process were MRI scans (€206/US$228) and consultations (€163/US$181 for tertiary hospitals and €80/US$89 for general hospitals). 10 To determine the maximum extra costs of a potential future diagnostic strategy at which it could still be cost saving, we did not include potential costs of the new diagnostic test. All costs and probabilities are shown in Table 2 . To address uncertainty, we conducted a probabilistic sensitivity analysis using Monte Carlo Simulation (repeated random sampling) with 1000 samples. Distributions were estimated for the probability of VS, the probability of other pathology and the probability of other important pathology. This sensitivity analysis quantifies the level of confidence of the model's conclusions. Based on the simulation, 95%
| Analysis
Confidence Intervals (CI) of mean costs per patient and savings were calculated using the percentile method in Excel 2007 (Microsoft).
| RESULTS
The results of the decision analytical model show that the mean expected costs per patient in the current diagnostic strategy are €399 (95%CI €398 -€401) or US$442 (95%CI US$359 -US$445). In 
€111 -€123) or US$129 (95%CI US$123 -US$136). If it is possible
to distinguish between patients with and without pathology, as described in strategy 2, mean savings per patient will be €256 (95% CI €250 -€262) or US$284 (95%CI US$277 -US$291). The cost of diagnosis will be €143 (95%CI €136 -€151) or US$159 (95%CI US $151 -US$167). 
| Strengths and limitations
The major strength of this study is that it is the first study to assess the potential benefits of hypothetical diagnostic strategies for VS.
This information can aid better informed decision making in research and development and can prevent investments in lower value strategies. There are multiple studies which investigate the role of MRI in the diagnostic pathway of VS and searched for an effective diagnostic algorithm to reduce the number of negative MRIs. However, none of these studies quantified the savings that might be achieved when the current diagnostic strategy would be improved. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Our results show the merits of future research to focus on optimising these diagnostic algorithms. Furthermore, most diagnostic VS studies do not mention patients with pathology other than VS. 11, 12, [14] [15] [16] [17] [18] [19] [20] [21] [22] In our diagnostic model, patients at risk of VS who turn out to have other relevant pathology were incorporated, because these pathologies are also being detected in the current diagnostic strategy. The incorporation of other pathology allowed us to not only evaluate the diagnostic cost of detecting VS patients, but also of patients with other pathology.
Some potential limitations should also be discussed. First, our model solely used costs to calculate possible savings, whereas effects (and costs) of (missed) diagnosis were not incorporated. Currently, literature about the consequences of false-negative results is lacking. We assumed that the sensitivity of MRI in the current strategy and the sensitivity of the test in new diagnostic strategies were 100%, that is effects would be similar for both strategies. In reality, the sensitivity of potential new tests will probably be lower than 100% (ie VSs and other pathologies could be missed in the future). Fourth, all costs are based on Dutch healthcare prices and may therefore slightly differ from other countries. The same applies to probabilities based on expert opinion, which can differ between hospitals and countries. We expect small differences in exact costs for other countries, but a similar trend. Given the detailed presentation of the model and its input parameters, those interested can assess the transferability of the results to their specific situation.
| Implications for clinical practice
Two important implications for daily clinical practice and research follow from the results of this study. First, although the proposed strategies in this study are hypothetical, they provide valuable insight into the potential benefits that new diagnostic strategies might have.
As calculated savings per patient are over €250 and annual savings range between €2.8 and €3.2 million for the Netherlands and €10.8 | 289
and this pathology should therefore not be missed. Hence, a potential new diagnostic strategy where all important pathology is detected will likely provide most value for money. We believe that when research is initiated into more effective strategies for diagnosing VS, these should also put effort into diagnosing other important pathology.
In conclusion, the model shows that substantial savings could be generated if we would be able to further optimise the diagnosis of patients suspected of VS.
